The knockout of Col4a3 in mice is used as a model of Alport syndrome. Knockout mice develop glomerular disease associated with neutral lipid accumulation in the kidney and progressive renal failure, which can be treated with lipid-lowering agents.
Semaglutide, the glucagon-like peptide 1 receptor agonist from Novo Nordisk A/S, which has seemingly improved every disease it’s been tested on, was a focus at Kidney Week 2024, where researchers presented data from multiple clinical studies in patients with kidney diseases.
Researchers at the Stony Brook University Renaissance School of Medicine performed a screening in search of Kruppel-like factor 15 (KLF15) agonists for treating proteinuric injuries in the kidney.
Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available for the prevention of BKV-associated nephropathy. Researchers from Aicuris Anti-infective Cures GmbH presented preclinical data on AIC-468, an antisense RNA therapy that inhibits the splicing process of a viral mRNA encoding a protein critical for BKV replication.
Researchers from Southern Medical University and affiliated organizations presented the discovery and preclinical characterization of novel human urate transporter 1 (hURAT1) inhibitors being developed for the treatment of hyperuricemia.
Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to take a gene therapy for a kidney disease into the clinic. The money enables the company to move the lead program, PS-002, for the treatment of IgA nephropathy to clinical proof of concept and advance programs in other complement-mediated kidney diseases, and in an undisclosed glomerular kidney disease.
Ono Pharmaceutical Co. Ltd. has patented tricyclic prostaglandin E2 receptor EP3 subtype (PTGER3; EP3) agonists potentially useful for the treatment of renal diseases.
Researchers from Renmin Hospital of Wuhan University have assessed the role of ankyrin repeat domain 1 (ANKRD1) in renal ischemia-reperfusion injury (IRI), which is the primary cause of acute kidney injury (AKI).
Harbin Medisan Pharmaceutical Co. Ltd. has synthesized PPARδ agonists reported to be useful for the treatment of fibrosis, neurodegeneration, inflammation, cardiovascular, cerebrovascular, autoimmune and metabolic disorders.
RSS
